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Background/Aims: To assess the value of hepatic-arterial-phase computed tomography (HAP-CT) versus ultrasound
(US) plus a-fetoprotein (AFP) in the surveillance of cirrhotic patients with previously treated hepatocellular carcinoma
(HCC).
Methods: Thirty-six cirrhotic patients, treated for single nodular HCC < 4 cm with complete response and no
evidence of other focal lesions, were enrolled in a prospective study and underwent simultaneous AFP/US/spiral-CT
follow-up every 6 months. Focal lesions were considered recurrences when they appeared as globular enhancement
areas (EA) at HAP-CT and increased in size during the follow-up.
Results: Fifteen of 36 patients showed at least one focal lesion for a total of 43 EA: 38/43 increased in size, four did not
change and one disappeared. EA were first observed after a follow-up of 9 6 4 (range 6–18) months. At the same time,
no patient had either nodular lesion at US examination or diagnostic levels of AFP. In 22 matched lesions, diagnosis by
CT was 8.2 6 3.5 months earlier than by US. In 13 patients, one evolved EA was submitted to US-guided biopsy and
histological examination showed HCC in all cases.
Conclusions: Periodical spiral-CT examination is more effective than US-AFP in early detection of HCC recurrence
in cirrhotic patients successfully treated for HCC.
q 2003 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most
common malignancy worldwide and is commonly observed
in the clinical course of chronic fibrotic liver diseases,
particularly liver cirrhosis secondary to chronic hepatitis C
virus (HCV) and HBV infection [1,2].
Surveillance for HCC in these clinical settings has
become part of the clinical practice of hepatologists.
Recommended screening for HCC in cirrhosis is based on
measurement of a-fetoprotein (AFP) and ultrasound (US)
examination of the liver every 6 months, sensitivity and
specificity of US being 71 and 93%, respectively [2,3]. US
detects nodular lesions. 20 mm, but has a lower sensitivity
when nodules are of 10–20 mm, and is often unable to
detect nodules , 10 mm [4]. However, the positive
predictive value of US is only 14%, at least in HBsAg
carriers [2]. In the absence of specific recommendations, the
same approach is currently used also for patients who have
been successfully treated for HCC [2,3]. However, in this
latter group of patients, the risk of recurrence of HCC and/or
appearance of new lesions in other liver segments is
dramatically high [5,6]. In addition, data regarding the
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follow-up of this particular group of patients are scarce. It is
therefore important to improve surveillance in this condition
and to assess the effectiveness of different diagnostic tech-
niques in detecting the occurrence of new neoplastic foci as
early as possible.
Spiral computed tomography (SCT) allows to scan the
upper abdomen in less than 25 s and so the entire liver
parenchyma in a single breath hold, during the hepatic
arterial phase (HAP) after administration of contrast
material. Previous studies showed that HAP-CT has an
excellent sensitivity in the detection of HCC , 1 cm
[7–10]. To evaluate the role of HAP-CT in the screening
for HCC in cirrhotic patients with previously treated HCC,
we designed a prospective investigation comparing SCT
with ultrasound examination.
2. Patients and methods
Thirty-six patients (21 males, mean age 63.5 ^ 7.4, range 50–74 years)
with cirrhosis of the liver, referred to the radiological unit, Department of
Clinical Pathophysiology, University of Florence School of Medicine from
January 2000 to December 2001 for surveillance after treatment for
hepatocellular carcinoma (HCC), gave their informed written consent to
participate in this prospective study, approved by the local Ethics
Committee in November 1999. Cirrhosis was HCV-related in 22, HBV-
related in three, and alcoholic in 11 patients. Twenty-one out of the
36 patients studied were in class A and 15 in class B, according to Child–
Pugh classification [11]. The previous HCC always appeared as a single
nodular lesion with a diameter , 4 cm and was diagnosed by pathological
analysis in 14 patients and non-invasive, radiological criteria in the
remaining 22 patients, according to the Barcelona EASL – 2000
Conference [3], i.e. focal lesion . 2 cm with arterial hypervascularization,
as assessed using two coincident imaging techniques. For this purpose, we
performed SCT and magnetic resonance (MR) imaging. All patients were
treated by surgical resection (n ¼ 8) or percutaneous ethanol injection with
complete response and no other focal lesions at both US and SCT, per-
formed 4 weeks later [3]. At that time, AFP was, 10 ng/ml in all patients.
Two patients also had a liver angioma, identified at SCT and confirmed
by MR.
After treatment, patients underwent surveillance by US and AFP
measurements every 6 months. In addition, they underwent SCT every
6 months. US and SCT were performed simultaneously (maximum interval:
one week) by independent radiologists that were unaware of the purposes of
the study.
2.1. Ultrasound
Ultrasound was performed using a ‘ASTRO MP’ echograph (Esa
Ote-Ansaldo, Genoa, Italy) equipped with wide-angle convex probes of
3.5 MHz, pulsed waves and power Doppler module. All US examinations
were performed by a skilled radiologist with 20 years of experience in this
field.
2.2. Spiral computed tomography
SCT was performed using a Somatom Plus (Siemens, Erlangen,
Germany) scanner. Spiral scans were obtained cephalocaudal with section
thickness of 5 mm and pitch 1.5 (reconstruction 4.5 mm); matrix
512 £ 512; at 170 or 220 mAs, and 120 kV, in 25 patients. In the remaining
11 patients, who had a longer liver, spiral scans were obtained with section
thickness of 8 mm and pitch 1.25 (reconstruction 6 mm). The entire liver
parenchyma was thus scanned within a single breath hold of about 20 s.
Three acquisitions were obtained in each patient: one before (basal
acquisition or direct scan) and two after the intravenous administration of
1.5 ml/kg body weight of non-ionic iodinated contrast material (Ultravist
370 Schering, Berlin, 3 ml/s), respectively. The first enhanced CT scan
started 25 s after the beginning of the injection of contrast material (HAP),
the second was initiated 70 s after the bolus (portal venous phase, PVP).
Each examination was completed in approximately 5–6 min. The referred
parameters allow detection of focal lesions . 3 mm.
Focal lesions observed at STC were considered suspect for HCC
when they appeared either as globular EA or hypovascular lesions at HAP
[8,9,12–14]. Occurrence of the ‘wash-out phenomenon’ at PVP reinforced
our suspicion [12]. However, suspect EA (SEA) having a diameter
, 15 mm are usually undetectable at either baseline examination and PVP.
Transient hepatic attenuation differences (THAD) were defined as
perfusion abnormalities that are visible exclusively during HAP; they are
usually wedge-shaped, but sometimes they appear round or round-like [15].
All CT scans were evaluated in blind fashion by the examiner and two
other devoted radiologists from the SCT service at our Institution, who
examined the images independently and were unaware of either the
clinical characteristics of the patients or the results of US examination.
Disagreement among the readers with regard to presence, number and
characters of nodules was solved by consensus. Each EA was assigned,
based on its diameter, to one of the following groups:, 5;, 10;. 10 and
. 20 mm. All patients with at least one SEA continued with both SCT
and AFP/US at 6 months’ interval until at least one lesion was suitable for
liver biopsy.
2.3. Statistical analysis
Data are given as the mean ^ SD. Correlation between US and SCT
was analysed by Spearman’s coefficient while chi-square test was used for
distribution analysis. The significance level was set at P , 0:05.
3. Results
All patients had a good compliance with the surveillance
program. In seven patients, however, STC and/or US were
performed with an interval ranging from 5 to 8 months. The
mean follow-up in the 36 patients included in the study was
18 ^ 6 (range 6–33) months.
Twenty-one out of these 36 patients developed no focal
lesions throughout the follow-up at either SCT and US. In
this group of patients, AFP was within the normal range
throughout the study. The remaining 15 patients (12 males,
mean age 64.5 ^ 8.0, range 50–74 years) showed at least
one focal lesion during the follow-up. All but two focal
lesions identified by SCT were SEA, the remaining two
lesions (observed in patients 7 and 10, respectively) were
THAD. We did not observe any hypovascular lesion. Indi-
vidual data of the 15 patients with SEA are shown in Table 1.
In four patients (nos. 1, 2, 4, and 8, Table 1), one SEA
occurred in the same place of the previously treated HCC,
and was therefore considered a treatment failure. In two
out of these 15 patients (nos. 9 and 10) the pre-existing
angiomas were also detected. The mean follow-up of these
15 patients was 20 ^ 5 (range 12–30) months. SEA were
first observed after a follow-up of 9 ^ 4 (range 6–18)
months. As shown in Table 1, at the first positive STC, one
patient had one SEA, five had two SEA, and nine had three
or more SEA, for a total of 43 lesions. Among them, five had
a diameter . 10 mm (Table 1); three of these latter lesions
were also appreciable at PVP. Thirty-eight out the 43 SEA
(88%) showed an increase in their size during the follow-up
(Figs. 1 and 2), four did not change and one became
undetectable (Fig. 3 and Table 1). Thirty-two evolving SEA
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had a detectable increase in their volume at the SCT
performed 6 months later; in six more lesions the increase
was detected at the 12 months’ examination. In addition,
four patients developed eight more lesions during the
follow-up (Table 1). US performed at the same time of the
first positive SCT did not detect any nodular lesion. US
performed 6 months later was able to identify eight lesions
in six patients. Twelve months later, US detected 12 lesions
in seven more patients. All together, in 22 matched lesions,
diagnosis was 8.2 ^ 3.5 months earlier by SCT than by US.
Table 1
Individual data of the 15 patients who showed at least one suspect enhancement area at hepatic arterial phase of spiral computed tomographya
Patient no. Age (years) Sex FU (months) I exam II exam III exam IV exam
SCT Echo SCT Echo SCT Echo SCT Echo
1 62 M 24 ,5 – .10 .10 .10 .10 DD DD
,5 – .10 – .20 .20B
,10 – .10 – ,20 .20
.10R – .20 .20 .20 .20
,10 – .10 .10
.10 –
2 68 F 18 ,5 – ,10 – .10 .10B
,10 – ,10 – ,10 –
,10R – ,10 – .10 .10
,10 – ,10 – ,10 –
3 74 F 30 ,5 – ,10 –
,5 – ,10 –
4 71 M 24 ,5 – ,10 – .10 .10 .20 .20B
,10R – ,10 – .10 .10 .10 .10
.10 – .10 – – – – –
,5 – ,5 – ,10 –
5 70 F 27 ,5 – ,10 – ,10 –
,5 – ,10 – .10 .10B
,10 – .10 .10 .10 .10
,10 – .10 .10
,10 – .10 –
6 64 M 18 ,10 – .10 .10B
,10 – ,10 –
,10 – .10 –
7 54 M 16 ,5 – ,10 –
,5 – .10 .10B
,5 – .10 .10
,5 – .10 –
8 53 M 18 ,10 – .10 – .20 .20B
.10 – .10 – .10 .10
.10R – .10 – .20 .20
,10 – .10 –
.10 –
.10 –
9 72 M 12 ,5 – ,10 –
,5 – ,10 –
,5 – ,10 –
,5 – ,10 –
.10 – .20 .20B
10 63 M 24 ,5 – ,10 –
,5 – .20 .20B
11 69 M 18 ,5 – ,10 – .10 .10B
12 55 M 18 ,5 – ,10 – ,10 –
,10 – ,10 – .10 .10B
13 72 M 26 ,5 – ,10 – ,10 –
,5 – ,10 – .10 .10B
,10 – ,10 – .10 .10
14 50 M 18 ,5 – ,10 –
,5 – ,10 –
15 71 M 18 ,5 – ,5 – ,10 –
,10 – .10 – .10 .10B
a B, biopsy; DD, diffuse disease; FU, follow-up; R, local recurrence.
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Finally, in two patients with four evolving lesions, US
performed 6 months later was negative (Table 1).
Ultrasound and SCT data were strictly related
(Spearman’s r ¼ 0:995, P , 0:0001) without differences
in distribution (chi-square test: not significant).
When SCT detected the first SEA, AFP was , 10 ng/ml
in 12 patients, and slightly increased (12, 28 and 41 ng/ml)
in the remaining three (nos. 8, 1 and 5, respectively). This
parameter did not show appreciable changes in eight
patients (from 7.40 ^ 1.40 to 9.70 ^ 3.80 ng/ml), while
it increased in seven (from 15.50 ^ 13.60 to
148.40 ^ 175.10 ng/ml). However, AFP became
. 100 ng/ml only in two patients (nos. 8 and 15) and
. 400 ng/ml in the patient (no. 1) who developed a diffuse
disease.
In 13 patients, one evolved SEA was submitted to
US-guided biopsy. Histological examination showed HCC
in all cases.
4. Discussion
The limits of serial AFP measurements and repeated US
in the screening of HCC are well known. In the opinion of
some authors [16,17] these procedures have no substantial
impact on the overall survival of cirrhotic patients with
HCC. Indeed, the high rate of early recurrence of HCC after
PEI or surgery in patients with a single nodule at US
remarks the low sensitivity of US in the staging of originally
multiple HCC [18]. On the other hand, pathological studies
[19] suggest that only half of the nodules , 1 cm in size
detected at US correspond to HCC.
Spiral computed tomography (or MR) is recommended
for confirmation and staging but not for screening of HCC
[3] due to its invasiveness and high cost. However, SCT is
very accurate in the diagnosis of HCC, since it recognizes
the development of the new, pathological arterial vascular-
ization; the results of previous studies by us [12] and others
[7–9] clearly indicate that SCT has a remarkably greater
sensitivity than US in identifying HCC nodules, especially
when they are, 10 mm. Of course, the neoplastic nature of
these nodules cannot be established by biopsy, since they
are observed only at HAP-CT, but it can be confirmed with
confidence by observing a growth at the following SCT
scans. In the present study, SEA were followed up every
6 months using SCT and were considered HCC when they
had an arterial enhancement and increased in size over a
6–12-month interval (Figs. 1 and 2). Non-neoplastic
nodules, even if they show arterial enhancement, do not
increase in size for a long period [20]. The results of liver
biopsy, performed on 13 SEA showing an increment in their
size, confirm our assumption.
With this approach, diagnosis of HCC in our series of
patients was earlier with SCT than with conventional, grey-
scale US and could become even shorter if the second,
confirmatory SCT is performed earlier (e.g. after 3 months).
Data on HCC growth [21] suggest that the time from
undetectable to 2 cm tumour is about 4–12 months. Further
investigations are needed to identify the most appropriate
interval.
Recently, contrast-enhanced ultrasound was found to
improve the sensitivity of conventional US in the diagnosis
of HCC [22]. Further studies are needed to establish whether
Fig. 1. Case 10. Serial CT examinations in a patient who underwent
partial right resection for single HCC nodule. HAP-CT contiguous
slices. The 18 months’ CT examination (a,b) showed a SEA < 5 mm
(black arrow), that reached 20 mm in diameter at follow-up CT
performed 6 months later (c,d).
Fig. 2. Case 5. CT follow-up at 15 (a), 21 (b) and 27 (c) months. HAP-CT images at the same level of scan. Twelve months’ evolution of a SEA (black
arrow) located in a poorly detectable site by US.
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this new technique would compare more favourably with
SCT.
In the current study, 88% of all SEA showed an incre-
ment and could therefore be considered recurrent HCC.
These data agree with those by Baron et al. [23], who
reported that in patients with cirrhosis of the liver, 92% of
all enhancement areas at HAP are HCC. With respect to this
point, it should be noted that the current investigation was
performed in patients with previous HCC. It is well known
that a fundamental step in the natural history of HCC is the
disappearance of portal vessels, which are substituted with
arteries. Furthermore, the total amount of arterial vascular-
ization was found to increase as HCC became more malig-
nant. So, arterial vascularity could be related with the ‘age’
and/or the degree of dedifferentiation of HCC [24]. There-
fore, recurrent tumours are more likely to be hypervascular
with respect to primary nodules, so explaining the greater
diagnostic accuracy of SCT at HAP in this setting. Whether
the results of the current investigation also apply to patients
with no previous tumour remains to be established.
In patients with cirrhosis, a small number of enhance-
ment areas observed at the HAP of SCT are due to benign
lesions, including THAD, haemangioma, hepatic peliosis,
fibrosis, splenic lobule and cryptogenic causes [20,23,25],
or, less probably, regenerating or dysplastic adenomatous
nodules [26]. It has been reported that only 4% of the latter
lesions show an enhancement during HAP and this enhance-
ment preludes malignant transformation in most cases [26].
In our investigation, we found only four (9%) non evolving
lesions. With respect to their nature, most of the above
possibilities can reliably be excluded, since all non evolving
SEA in this study were not detected when SCT was per-
formed before and 30 days after treatment. We also found
one disappearing SEA (Fig. 3): in this case the most prob-
able cause is a THAD, due to a little portal obstruction or
artero-portal shunt.
In patients with cirrhosis and HCC, survival has
improved because of early diagnosis [27]; so it is highly
probable that an early diagnosis of recurrence in patients
with previous HCC would also result in an improved
survival and/or quality of life. In fact, patients with small
tumours may be better candidates for liver transplantation
and could remain in the waiting list for a longer time. Liver
resection is also more feasible in patients with small lesions,
as usually are those detected at HAP-CT. If these options are
not suitable, patient could be referred to chemoembolization
with cisplatin or doxorubicin, an approach found to improve
survival in a recent meta-analysis [28]. Of course, percu-
taneous treatment such as ethanol injection or radio-
frequency ablation is currently not suitable when HCC is
detected only at HAP of SCT. Investigations are currently in
progress at our Institution aiming at identifying and submit
to percutaneous therapy small HCC detected at SCT using
‘targeted’ US with second-generation contrast agents.
Whether this policy would enable an earlier treatment of
small tumours remains to be confirmed; anecdotal cases
encourage our attempt.
In conclusion, the results of the present investigation
suggest that periodical SCT is more effective than conven-
tional US for the screening of HCC in patients with cirrhosis
of the liver successfully treated for a previous HCC. All
nodules that show both an arterial enhancement at HAP and
an increase in their size at subsequent SCT should be
considered recurrent HCC. Further studies are needed to
clarify whether SCT could be more effective than US also in
cirrhotic patients without previous HCC.
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